ArticleFertility and sterility2010
The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells.
Article in Fertility and sterility, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 48 citations in OpenAlex.
- Progesterone signaling in uterine fibroids: Molecular mechanisms and therapeutic opportunities.Life sciences · 2025Review
- Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility.Endocrine reviews · 2020Review
- The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium.International journal of molecular sciences · 2019Review
- Uterine fibroids: an update on current and emerging medical treatment options.Therapeutics and clinical risk management · 2019Review
- Selective progesterone receptor modulators for fertility preservation in women with symptomatic uterine fibroids.Biology of reproduction · 2017Review
- Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium.Human reproduction (Oxford, England) · 2017Article
- Anti-Tumoral Effects of Anti-Progestins in a Patient-Derived Breast Cancer Xenograft Model.Hormones & cancer · 2016Article
- Endocrinology of uterine fibroids: steroid hormones, stem cells, and genetic contribution.Current opinion in obstetrics & gynecology · 2015Review
- Antiprogestins in gynecological diseases.Reproduction (Cambridge, England) · 2015Review
- Expression of a mitochondrial progesterone receptor (PR-M) in leiomyomata and association with increased mitochondrial membrane potential.The Journal of clinical endocrinology and metabolism · 2014Article
- A new strategy for selective targeting of progesterone receptor with passive antagonists.Molecular endocrinology (Baltimore, Md.) · 2013Article
- Nuclear receptors and their selective pharmacologic modulators.Pharmacological reviews · 2013Review
- The role of progesterone signaling in the pathogenesis of uterine leiomyoma.Molecular and cellular endocrinology · 2012Review
- Treatment for Uterine Fibroids: Searching for Effective Drug Therapies.Drug discovery today. Therapeutic strategies · 2012Article
- Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications.Human reproduction updateReview
- Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications.Human reproduction updateReview
- Proceedings from the Third National Institutes of Health International Congress on Advances in Uterine Leiomyoma Research: comprehensive review, conference summary and future recommendations.Human reproduction updateArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
objectiveTo evaluate the effects of selective P receptor (PR) modulator CDB4124 on cell proliferation and apoptosis in cultured human uterine leiomyoma smooth muscle (LSM) cells and control myometrial smooth muscle (MSM) cells in matched uteri.
designLaboratory research.
settingAcademic medical center. PATIENT(S): Premenopausal women (n = 12) undergoing hysterectomy for leiomyoma-related symptoms. INTERVENTION(S): Treatment of primary LSM and MSM cells with CDB4124 (10(-8)-10(-6) M) or vehicle for 24, 48, or 72 hours. MAIN OUTCOME MEASURE(S): Western blot for protein expression of proliferating cell nuclear antigen, cleaved polyadenosine 5'-diphosphate-ribose polymerase, Bcl-2, and Krüppel-like transcription factor 11; 93-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) assay to evaluate viable cell numbers; and real-time polymerase chain reaction (PCR) to quantify messenger RNA (mRNA) levels. RESULT(S): Treatment with CDB4124 significantly decreased levels of the proliferation marker proliferating cell nuclear antigen, the number of viable LSM cells, and the antiapoptotic protein Bcl-2. On the other hand, treatment with CDB4124 increased levels of the apoptosis marker cleaved polyadenosine 5'-diphosphate-ribose polymerase and the tumor suppressor Krüppel-like transcription factor 11 in a dose- and time-dependent manner in LSM cells. In matched MSM cells, however, CDB4124 did not affect cell proliferation or apoptosis. CONCLUSION(S): CDB4124 selectively inhibits proliferation and induces apoptosis in LSM but not in MSM cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.